Details of the Drug Combination

General Information of Drug Combination (ID: DCE35VL)

Drug Combination Name

Azelaic Acid Minocycline

Indication

Disease Entry	Status	REF
Rosacea	Phase 4	[1]

Component Drugs

Azelaic Acid DMHVL0J

Minocycline DMVN5OH

Small molecular drug

2D MOL

3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indication(s) of Azelaic Acid

Disease Entry	ICD 11	Status	REF
Acne vulgaris	ED80	Approved	[2]

Azelaic Acid Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Oxo-5-alpha-steroid 4-dehydrogenase (SRD5A)	TT2A0DR	S5A1_HUMAN; S5A2_HUMAN; PORED_HUMAN	Inhibitor	[6]
------------------------------------------------------------------------------------

Azelaic Acid Interacts with 6 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Urokinase-type plasminogen activator (PLAU)	OTX0QGKK	UROK_HUMAN	Decreases Expression	[7]
Tissue-type plasminogen activator (PLAT)	OTQPDNAB	TPA_HUMAN	Decreases Expression	[7]
Plasminogen activator inhibitor 1 (SERPINE1)	OTT0MPQ3	PAI1_HUMAN	Increases Expression	[7]
Peroxisome proliferator-activated receptor gamma (PPARG)	OTHMARHO	PPARG_HUMAN	Increases Expression	[8]
Guanine nucleotide-binding protein G(olf) subunit alpha (GNAL)	OTESDTEU	GNAL_HUMAN	Increases Response To Substance	[9]
Guanine nucleotide-binding protein subunit alpha-15 (GNA15)	OTFYRZGV	GNA15_HUMAN	Increases Response To Substance	[9]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 DOT(s)

Indication(s) of Minocycline

Disease Entry	ICD 11	Status	REF
Acne vulgaris	ED80	Approved	[3]
Actinomycosis	N.A.	Approved	[3]
Acute gonococcal cervicitis	N.A.	Approved	[3]
Bacterial infection	1A00-1C4Z	Approved	[4]
Bartonellosis	N.A.	Approved	[3]
Bronchitis	CA20	Approved	[3]
Brucellosis	N.A.	Approved	[3]
Chancroid	N.A.	Approved	[3]
Listeriosis	N.A.	Approved	[3]
Lymphogranuloma venereum	N.A.	Approved	[3]
Ornithosis	N.A.	Approved	[3]
Periodontitis	DA0C	Approved	[3]
Pneumonia	CA40	Approved	[3]
Q fever	N.A.	Approved	[3]
Relapsing fever	N.A.	Approved	[3]
Rickettsialpox	N.A.	Approved	[3]
Rocky mountain spotted fever	N.A.	Approved	[3]
Syphilis	N.A.	Approved	[3]
Trachoma	N.A.	Approved	[3]
Tularemia	1B94	Approved	[3]
Typhus	N.A.	Approved	[3]
Urinary tract infection	GC08	Approved	[3]
Yaws	N.A.	Approved	[3]
Rosacea	ED90.0	Phase 2	[5]
Plague	N.A.	Investigative	[3]
Sinusitis	CA0A.Z	Investigative	[3]
Vibrio cholerae infection	1A00	Investigative	[3]

Minocycline Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Staphylococcus 30S ribosomal subunit (Stap-coc pbp2)	TTQ8KVI	F4NA87_STAAU	Binder	[10]
------------------------------------------------------------------------------------

Minocycline Interacts with 1 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Cytochrome P450 2E1 (CYP2E1)	OTHQ17JG	CP2E1_HUMAN	Increases ADR	[11]
------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT05014906) Efficacy of Oral Minocycline (Solodyn) and Oral Minocycline (Solodyn) Plus Azelaic Acid (Finacea) for Acne Rosacea
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7484).
3	Minocycline FDA Label
4	Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52.
5	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6	Inhibition of 5 alpha-reductase activity in human skin by zinc and azelaic acid. Br J Dermatol. 1988 Nov;119(5):627-32.
7	Azelaic acid decreases the fibrinolytic potential of cultured human melanoma cells in vitro. Cancer Lett. 1996 Jun 5;103(2):125-9. doi: 10.1016/0304-3835(96)04185-7.
8	Azelaic acid modulates the inflammatory response in normal human keratinocytes through PPARgamma activation. Exp Dermatol. 2010 Sep;19(9):813-20. doi: 10.1111/j.1600-0625.2010.01107.x. Epub 2010 Jul 2.
9	Identification of specific ligands for orphan olfactory receptors. G protein-dependent agonism and antagonism of odorants. J Biol Chem. 2005 Mar 25;280(12):11807-15. doi: 10.1074/jbc.M411508200. Epub 2004 Dec 14.
10	Functional, biophysical, and structural bases for antibacterial activity of tigecycline. Antimicrob Agents Chemother. 2006 Jun;50(6):2156-66.
11	ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.